Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | — | — |
No adverse event; HCP/Medical Assistant called to report that 2 adults received pediatric doses of RECOMBIVAX HB. One was administered on 3/5/2025 and the other on 2/25/2025. No other information was available at the time of the call. No adverse effects were reporte; HCP/Medical Assistant called to report that 2 adults received pediatric doses of RECOMBIVAX HB. One was administered on 3/5/2025 and the other on 2/25/2025. No other information was available at the time of the call. No adverse effects were reporte; This spontaneous report was received from a physician assistant and refers to an adult patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant medications and previous drugs reactions or allergies were not reported. On 05-MAR-2025, the patient was vaccinated with a dose of hepatitis b vaccine (recombinant) suspension for injection (RECOMBIVAX HB) 0.5 mL, administered as prophylaxis (strength, Lot No., expiration date, dose number, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided). It was reported that the patient received a pediatric dose of the previous mention vaccine (product administered to patient of inappropriate age) (underdose). No additional adverse event was reported (no adverse event). This is one of two reports received from the same reporter.; Reporter's Comments: